(CIDRAP News) The Food and Drug Administration (FDA) published a notice in the Federal Register this week to make clear that doxycycline and penicillin G procaine, along with ciprofloxacin, already are approved for use as postexposure prophylaxis following inhalational exposure to anthrax. The notice also details postexposure dosing regimens for these medications.
(CIDRAP News) The Centers for Disease Control and Prevention (CDC) gives a detailed report on its ongoing investigation of the current anthrax attack in today's issue of Morbidity and Mortality Weekly Report. The report includes a detailed treatment protocol for inhalational anthrax related to the current attack, calling for use of either ciprofloxacin or doxycycline plus one or two other antimicrobials.
Oct 25 (CIDRAP News) Two studies published online by Nature this week help explain how anthrax toxin works, possibly paving the way for the development of drugs that could block the toxin's action. One group of researchers explains how it identified the cell-surface receptor that enables anthrax toxin to invade host cells, while another group describes the precise molecular structure of a key component of the toxin.
